Conversion to mammalian target of rapamycin inhibitors increases risk of de novo donor‐specific antibodies

Publisher： John Wiley & Sons Inc

E-ISSN： 1432-2277|27|8|775-783

ISSN： 0934-0874

Source： TRANSPLANT INTERNATIONAL (ELECTRONIC), Vol.27, Iss.8, 2014-08, pp. : 775-783

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

De novo donor‐specific anti‐HLA antibodies mediated rejection in liver‐transplant patients

By  

TRANSPLANT INTERNATIONAL (ELECTRONIC), Vol. 28, Iss. 12, 2015-12 ,pp. : 1371-1382

John Wiley & Sons Inc

Access to resources Recommend Favorite

Many de novo donor‐specific antibodies recognize β2‐microglobulin‐free, but not intact HLA heterodimers

By  

HLA, Vol. 87, Iss. 5, 2016-05 ,pp. : 356-366

John Wiley & Sons Inc

Access to resources Recommend Favorite

Results of early treatment for de novo donor‐specific antibodies in pediatric kidney transplant recipients in a cross‐sectional and longitudinal cohort

By  

PEDIATRIC TRANSPLANTATION, Vol. 22, Iss. 2, 2018-03 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

De Novo Donor‐Specific HLA Antibodies Are Associated With Rapid Loss of Graft Function Following Islet Transplantation in Type 1 Diabetes

By  

AMERICAN JOURNAL OF TRANSPLANTATION, Vol. 15, Iss. 12, 2015-12 ,pp. : 3239-3246

John Wiley & Sons Inc

Access to resources Recommend Favorite

Risk factors for the development of donor‐specific antibodies after pediatric heart transplantation

By  

PEDIATRIC TRANSPLANTATION, Vol. 19, Iss. 8, 2015-12 ,pp. : 906-910

John Wiley & Sons Inc

Access to resources Recommend Favorite